<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39362933</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab.</ArticleTitle><Pagination><StartPage>22981</StartPage><MedlinePgn>22981</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22981</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-74196-9</ELocationID><Abstract><AbstractText>We examined candidate biomarkers for efficacy outcomes in hospitalized COVID-19 patients who were treated with sirukumab, an IL-6 neutralizing antibody, in a randomized, double-blind, placebo-controlled, phase 2 trial. Between May 2020 and March 2021, 209 patients were randomized (sirukumab, n = 139; placebo, n = 70); 112 had critical COVID-19. Serum biomarkers were evaluated for the pharmacodynamic effect of sirukumab and for their potential prognostic and predictive effect on time to sustained clinical improvement up to Day 28, clinical improvement at Day 28, and mortality at Day 28. The absence of detectable IL-4 increase and smaller increases in CCL13 post-baseline were most significantly associated with better response to sirukumab (versus placebo) treatment for all clinical efficacy outcomes tested, especially in patients with critical COVID-19. These data suggest that patients with critical COVID-19 without detectable sirukumab-induced IL-4 levels are more likely to benefit from sirukumab treatment. ClinicalTrials.gov Identifier: NCT04380961.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Thys</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Loza</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, PA, Spring House, USA. mloza@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynn</LastName><ForeName>Linghua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IQVIA RDS, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callewaert</LastName><ForeName>Katleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varma</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, PA, Spring House, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crabbe</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Wesenbeeck</LastName><ForeName>Liesbeth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Landuyt</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Meyer</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aerssens</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbrugge</LastName><ForeName>Inge</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica NV, Beerse, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04380961</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>640443FU93</RegistryNumber><NameOfSubstance UI="C568922">sirukumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IL-4</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword></KeywordList><CoiStatement>K.C., M.C., L.V.W., E.V.L., and S.D.M. are employees of Janssen Pharmaceutica NV and may hold stock in Johnson &amp; Johnson. K.T., J.A., and I.V. were employees of Janssen Pharmaceutical NV at the time the study was performed. M.J.L. and L.V. are employees of Janssen Research &amp; Development, LLC and may hold stock in Johnson &amp; Johnson. L.Z. is an employee of IQVIA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39362933</ArticleId><ArticleId IdType="pmc">PMC11452205</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-74196-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-74196-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell. Host Microbe. 27, 992–1000e1003 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med.8, 1233–1244 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 326, 499–518 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261689</ArticleId><ArticleId IdType="pubmed">34228774</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19.) Accessed September 20. (2023). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19 (2021).</Citation></Reference><Reference><Citation>ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use [package insert] (Genentech, Inc., South San Francisco, CA, 2022).</Citation></Reference><Reference><Citation>Gottlieb, R. L. et al. The IL-6 hypothesis in COVID-19: a phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in confirmed severe or critical COVID-19. J Infect. 89, 106241 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39182655</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Guidance for industry. Assessing COVID-19-related symptoms on outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. Accessed September 20. (2023). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs (2020).</Citation></Reference><Reference><Citation>Tom, J. et al. Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with tocilizumab in a randomized controlled trial. Crit. Care Med.50, 398–409 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855771</ArticleId><ArticleId IdType="pubmed">34612846</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik, P. et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid. Based Med.26, 107–108 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7493072</ArticleId><ArticleId IdType="pubmed">32934000</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med.26, 1636–1643 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini, F. et al. The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved. Cytokine Growth Factor. Rev.58, 82–91 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837329</ArticleId><ArticleId IdType="pubmed">33573850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, Y. et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 5, e139834 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, L. et al. Longitudinal cytokine profile in patients with mild to critical COVID-19. Front. Immunol.12, 763292 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8685399</ArticleId><ArticleId IdType="pubmed">34938289</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha, D. et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 389, 1206–1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28215362</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijver, B. et al. Extensive longitudinal immune profiling reveals sustained innate immune activation in COVID-19 patients with unfavorable outcome. Eur. Cytokine Netw.31, 154–167 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937051</ArticleId><ArticleId IdType="pubmed">33648924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponthieux, F. et al. Tocilizumab-induced unexpected increase of several inflammatory cytokines in critically ill COVID-19 patients: the anti-inflammatory side of IL-6. Viral Immunol.35, 60–70 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35085462</ArticleId></ArticleIdList></Reference><Reference><Citation>Au-Yeung, B. B. &amp; Fowell, D. J. A key role for Itk in both IFN gamma and IL-4 production by NKT cells. J. Immunol.179, 111–119 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17579028</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres, K. C., Dutra, W. O., Gollob, K. J. &amp; Endogenous IL-4 and IFN-gamma are essential for expression of Th2, but not Th1 cytokine message during the early differentiation of human CD4 + T helper cells. Hum. Immunol.65, 1328–1335 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15556683</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga, J. &amp; Abraham, D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest.117, 557–567 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1804347</ArticleId><ArticleId IdType="pubmed">17332883</ArticleId></ArticleIdList></Reference><Reference><Citation>Belperio, J. A. et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J. Immunol.173, 4692–4698 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15383605</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue, T. et al. CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis. Eur. Respir J.24, 49–56 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15293604</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter, K. J. &amp; Hogaboam, C. M. Immunosuppressive effects of CCL17 on pulmonary antifungal responses during pulmonary invasive aspergillosis. Infect. Immun.73, 7198–7207 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1273903</ArticleId><ArticleId IdType="pubmed">16239514</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray, L. A. et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int. J. Biochem. Cell. Biol.40, 2174–2182 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18395486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharaee-Kermani, M., McCullumsmith, R. E., Charo, I. F., Kunkel, S. L. &amp; Phan, S. H. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine. 24, 266–276 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14609568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>